Trial Profile
An open-label trial assessing anti JCV-serostatus and antibody levels for progressive multifocal leukoencephalopathy-risk in natalizumab-treated MS-patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 27 Dec 2015 New trial record